TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03123224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Exercise + Caregiver Skills Training
Description: The combined moderate to high intensity combined aerobic and resistance exercise training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Balance and Flexibility + Caregiver Skills Training
Description: The stretching, balance and flexibility training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
Study: NCT01260259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: RIPC will be elicited in the operating room (OR) after anesthesia induction and before start of surgery. After placement of an arterial line, a tourniquet will be placed over a lower extremity. It will be inflated to 15 mmHg above systolic blood pressure for 5 minutes, and then deflated for 5 minutes. This cycle of inflation-deflation will be repeated another 3 times before surgery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: In OR, after induction of general anesthesia and arterial line placement, a deflated tourniquet will be placed over the lower extremity for 40 minutes.
Study: NCT01441596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's choice of treatment
Description: Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
Study: NCT03682913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-CIT protocol
Description: Personalized inhibitory control training for one week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: without personalized inhibitory control training for one week.
Study: NCT03223376

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: fruquintinib +paclitaxel
Description: treatment arm(fruquintinib +paclitaxel)- subjects will receive Fruquintinib orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: fruquintinib placebo + paclitaxel
Description: control arm(fruquintinib placebo + paclitaxel)- subjects will receive Fruquintinib placebo orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
Study: NCT01822392

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Parent Management Training (Interactive)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Parent Management Training (Recorded)
Study: NCT02816528

Intervention type: BEHAVIORAL
Intervention: Training program
Description: Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
Study: NCT03533244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% AG-86893 Eye Drops
Description: One drop, three times daily to the study eye for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% AG-86893 Eye Drops
Description: One drop, three times daily to the study eye for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Eye Drops
Description: One drop, three times daily to the study eye for 28 days
Study: NCT01886703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer Walking Program
Description: All subjects will be prescribed a low-intensity walking program based on their current activity level and an daily assigned step count goal (with the current physical activity recommendations of 30 minutes of moderate-to-vigorous activity per day or 150 minutes per week as the ideal goal). Participants will be provided with face-to-face counseling and written material describing their specific individualized walking program. Participants will also be instructed to maintain their normal activities as much as possible during the intervention period. Participants will be given a pedometer and instructed to wear it at least 5 days per week for the duration of the study.
Study: NCT02523573

Intervention type: PROCEDURE
Intervention: Adult ARF ICU patients needing BAL with HFNC
Description: bronchoalveolar lavage is performed in spontaneously breathing patients under high flow nasal cannula oxygen
Study: NCT03034993

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Text Messaging
Description: Subjects will receive text messages with reminders of their upcoming outpatient health care appointments at the Boston Health Care for the Homeless Program (BHCHP) clinic. The text message will indicate the time of the appointment and the location (e.g. Remember appointment Friday March 15 at 10am in the Yawkey building). Appointment reminder text messages will be sent 3 days ahead and again 1 day ahead of the appointment date. Medication related texts will be sent every other day and will be educational and motivational (e.g. Keep taking medications that way the doctor prescribed them, even if feeling fine). Mood related texts will also be sent every other day and ask about mood on a 1 to 5 scale. The participant will text back a response.
Study: NCT02719275

Intervention type: BEHAVIORAL
Intervention: Social Media Monitoring
Description: Retrospective analyses of social media activity prior to crisis.

Intervention type: BEHAVIORAL
Intervention: Social Media Monitoring
Description: Retrospective analyses of social media activity prior to crisis.

Intervention type: BEHAVIORAL
Intervention: Social Media Monitoring
Description: Retrospective analyses of social media activity prior to crisis.

Intervention type: BEHAVIORAL
Intervention: Social Media Monitoring
Description: Retrospective analyses of social media activity prior to crisis.
Study: NCT02063750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strengthening exercises using a Swiss ball
Description: This group performed eight muscle strengthening exercises using a Swiss ball of 65 cm diameter and dumbbells with different loads.~Each training session was 40 minutes long and was performed three times a week for 12 weeks. The exercises were performed in three sets of 12 repetitions, with an interval of one to two minutes of recovery between exercises, which alternated between upper limbs, lower limbs and abdomen. The load used was 60 % of one repetition maximum (1RM).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strengthening exercises
Description: The stretching group performed stretching exercises that targeted the same muscles trained in the IG. The participants remained in the stretched position for three sets of 30 s for each exercise. The total session time was 40 minutes.
Study: NCT01184430

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse contour cardiac output device
Description: Goal directed volume therapy using stroke volume variation and cardiac output to guide volume therapy and inotropic support.
Study: NCT03266796

Intervention type: BEHAVIORAL
Intervention: goal setting process
Description: goal setting process during the first consultation
Study: NCT03081780

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FATE-NK100
Description: Preparative regimen:~* Fludarabine 25 mg/m2 x 5 days start Day -6~* Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4~Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12.
Study: NCT03561649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: This trial will be conducted by rheumatologists who can follow patients with SpA and conduct this trial in good conditions and in accordance with regulatory and legal recommendations.
Study: NCT03681249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ShenqiDihuang Decoction
Description: ShenqiDihuang Decoction 150ml twice a day for 24 weeks 150ml twice a day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ShenqiDihuang Decoction placebo
Description: traditional Chinese medicine placebo mimic ShenqiDihuang Decoction 150ml twice a day for 24 weeks
Study: NCT04213495

Intervention type: OTHER
Intervention: Anesthesia
Description: Patients undergoing anesthesia from the cooperating Anesthesia center
Study: NCT04505527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lateral stepping
Description: Subjects will step laterally, changing direction every 10 m, thus alternating lead and lag limbs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lateral stepping
Description: Subjects will step laterally, changing direction every 10 m, thus alternating lead and lag limbs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lateral stepping
Description: Subjects will step laterally, changing direction every 10 m, thus alternating lead and lag limbs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forward walking
Description: Subjects will have a typical forward walking
Study: NCT03048227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Measurement (CGM)
Description: Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
Study: NCT05172115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional catheter-directed thrombolysis (CDT) with recombinant tissue plasminogen activator (rtPA)
Description: Conventional catheter-directed thrombolysis with fixed-dose of 24 mg tissue plasminogen activator infusion over 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Subcutaneous enoxaparin twice-daily (1mg/kg)
Study: NCT03929068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbidopa-levodopa
Description: Motivated by the success of dopaminergic drugs in treating rigidity associated with Parkinson's disease, some neurologists have used carbidopa-levodopa to attempt to improve spasticity in ALS and PLS patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo will be given to maintain blinding of participants and study team.
Study: NCT02723344

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: of Lactobacillus reuteri (L. reuteri; DSM 17938)
Description: Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower and medium chain triglyceride oils
Description: Placebo
Study: NCT00960219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-amino acid oxidase inhibition (DAAOI-1)
Description: 1g/day(500mg BID), oral, for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1# BID, oral, for 6 weeks
Study: NCT04708223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct restorative treatment with fast-curing composites (Tetric PowerFill/ Tetric PowerFlow)
Description: Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric PowerFill/ Tetric PowerFlow (test group) was cured for 3 s.

Intervention type: DEVICE
Group type: OTHER
Intervention: Direct restorative treatment with conventionally applied composites (Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill)
Description: Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill (control group) were conventionally cured for 10 s per increment.
Study: NCT03333941

Intervention type: DEVICE
Intervention: ReCell® Autologous Cell Harvesting Device
Description: RES (Regenerative Epithelial Suspension) derived from the use of the ReCell® device will be applied over skin grafts meshed more widely than conventional autografting.
Study: NCT00332670

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 10.000lux blue 1 hour every day during three weeks
Description: 10.000lux during 60 minutes, starting 1 hour after wake-up, during 3 weeks

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 50lux dim red 1 hour every day during three weeks
Description: 50 lux red light, 60 minutes every morning, starting 1 hour after wake-up, during three weeks
Study: NCT01591083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)
Description: Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score \>=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score \<6 are assigned to the control group.~In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)
Description: Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score \>=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score \<6 are assigned to the control group.~In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)
Description: Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score \>=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score \<6 are assigned to the control group.~In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days.
Study: NCT02207205

Intervention type: DRUG
Group type: OTHER
Intervention: Blood drawn from indwelling catheters versus direct venipuncture
Description: Evaluation of the source of blood samples on whole blood clotting time
Study: NCT03034993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Subjects will receive text messages with reminders of their upcoming outpatient health care appointments at the Boston Health Care for the Homeless Program (BHCHP) clinic. The text message will indicate the time of the appointment and the location (e.g. Remember appointment Friday March 15 at 10am in the Yawkey building). Appointment reminder text messages will be sent 3 days ahead and again 1 day ahead of the appointment date. Medication related texts will be sent every other day and will be educational and motivational (e.g. Keep taking medications that way the doctor prescribed them, even if feeling fine). Mood related texts will also be sent every other day and ask about mood on a 1 to 5 scale. The participant will text back a response.
Study: NCT01398111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate + Formoterol
Description: glycopyrrolate pMDI + formoterol pMDI
Study: NCT01777178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low bicarbonate dialysis
Study: NCT01948115

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: equimolar mixture of oxygen and nitrous oxide or medical air
Description: We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group placebo (medical air), 75 patients in group treatment (equimolar mixture of oxygen and nitrous oxide).~Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: equimolar mixture of oxygen and nitrous oxide or medical air
Description: We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group placebo (medical air), 75 patients in group treatment (equimolar mixture of oxygen and nitrous oxide).~Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention.
Study: NCT02983747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP Treatment(P)
Description: Ultrasound(Philips® iU22 ultrasound system) guided intra-disk injection using 2 ml of platelet rich plasma, containing 0.2 ml of calcium chloride(SINE®, SHANGHAI XINYI PHARMACEUTIAL Co . Ltd .) per treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication Treatment(Loxoprofen Sodium tablets,M)
Description: Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication Treatment(Loxoprofen Sodium tablets,M)
Description: Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
Study: NCT01818115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrus Implant
Study: NCT01398111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: glycopyrrolate pMDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: formoterol pMDI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pMDI
Study: NCT01153412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Osteopathic manipulation to determine balance and stability in elderly
Study: NCT00922571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FS Laser Surgery
Description: The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FS Laser System
Description: The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
Study: NCT00571506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone 4 mg tablets by mouth daily for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30 mg tablet by mouth once daily
Study: NCT04274647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE
Description: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
Study: NCT02806050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: all patients will be treated with palbociclib, on a 3 weeks on, 1 week off cycle until progression

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES PET
Description: all patients will have a FES PET at baseline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: all patients will be treated with Letrozole daily until progression
Study: NCT02265822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin in children premedication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam in children premedication
Study: NCT01398176

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3 ounces of mushrooms
Description: 3 ounces of mushrooms consumed daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6 ounces of mushrooms
Description: 6 ounces of mushrooms consumed daily for 4 weeks